Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Leukemia

  Free Subscription


Articles published in Cancer

Retrieve available abstracts of 64 articles:
HTML format



Single Articles


    October 2021
  1. ALDOSS I, Otoukesh S, Zhang J, Mokhtari S, et al
    Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemia.
    Cancer. 2021 Oct 11. doi: 10.1002/cncr.33967.
    PubMed     Abstract available


  2. KANTARJIAN HM, Jain N, Garcia-Manero G, Welch MA, et al
    The cure of leukemia through the optimist's prism.
    Cancer. 2021 Oct 6. doi: 10.1002/cncr.33933.
    PubMed     Abstract available


    September 2021
  3. JAMY OH, Dhir A, Costa LJ, Xavier AC, et al
    Impact of sociodemographic factors on early mortality in acute promyelocytic leukemia in the United States: A time-trend analysis.
    Cancer. 2021 Sep 8. doi: 10.1002/cncr.33914.
    PubMed     Abstract available


    August 2021
  4. NELSON AM, Amonoo HL, Kavanaugh AR, Webb JA, et al
    Palliative care and coping in patients with acute myeloid leukemia: Mediation analysis of data from a randomized clinical trial.
    Cancer. 2021 Aug 30. doi: 10.1002/cncr.33886.
    PubMed     Abstract available


  5. KENNEDY VE, Keegan THM, Li Q, Maguire FB, et al
    Frontline treatment patterns and outcomes among older adults with acute myeloid leukemia: A population-based analysis in the modern era.
    Cancer. 2021 Aug 26. doi: 10.1002/cncr.33873.
    PubMed     Abstract available


  6. KANTARJIAN HM, Begna KH, Altman JK, Goldberg SL, et al
    Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS).
    Cancer. 2021 Aug 23. doi: 10.1002/cncr.33828.
    PubMed     Abstract available


  7. KLISOVIC RB, Leung WH, Brugger W, Dirnberger-Hertweck M, et al
    A phase 2a, single-arm, open-label study of tafasitamab, a humanized, Fc-modified, anti-CD19 antibody, in patients with relapsed/refractory B-precursor cell acute lymphoblastic leukemia.
    Cancer. 2021 Aug 3. doi: 10.1002/cncr.33796.
    PubMed     Abstract available


  8. MAITI A, DiNardo CD, Qiao W, Kadia TM, et al
    Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score-matched analysis.
    Cancer. 2021 Aug 3. doi: 10.1002/cncr.33814.
    PubMed     Abstract available


    July 2021

  9. Erratum to "Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high-risk stratum of patients with newly diagnosed high-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group study AALL113
    Cancer. 2021 Jul 22. doi: 10.1002/cncr.33597.
    PubMed    


  10. KIM K, Maiti A, Loghavi S, Pourebrahim R, et al
    Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax.
    Cancer. 2021 Jul 13. doi: 10.1002/cncr.33689.
    PubMed     Abstract available


    June 2021
  11. VENUGOPAL S, Shoukier M, Konopleva M, Dinardo CD, et al
    Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy.
    Cancer. 2021 Jun 28. doi: 10.1002/cncr.33675.
    PubMed     Abstract available


  12. SAXENA K, Herbrich SM, Pemmaraju N, Kadia TM, et al
    A phase 1b/2 study of azacitidine with PD-L1 antibody avelumab in relapsed/refractory acute myeloid leukemia.
    Cancer. 2021 Jun 25. doi: 10.1002/cncr.33690.
    PubMed     Abstract available


  13. HOPPMANN AL, Chen Y, Landier W, Hageman L, et al
    Individual prediction of nonadherence to oral mercaptopurine in children with acute lymphoblastic leukemia: Results from COG AALL03N1.
    Cancer. 2021 Jun 23. doi: 10.1002/cncr.33760.
    PubMed     Abstract available


  14. SASAKI K, Kantarjian HM, Morita K, Short NJ, et al
    Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis.
    Cancer. 2021 Jun 17. doi: 10.1002/cncr.33655.
    PubMed     Abstract available


    May 2021
  15. NGUYEN HTK, Terao MA, Green DM, Pui CH, et al
    Testicular involvement of acute lymphoblastic leukemia in children and adolescents: Diagnosis, biology, and management.
    Cancer. 2021 May 25. doi: 10.1002/cncr.33609.
    PubMed     Abstract available


  16. BORTHAKUR G, Odenike O, Aldoss I, Rizzieri DA, et al
    A phase 1 study of the pan-bromodomain and extraterminal inhibitor mivebresib (ABBV-075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia.
    Cancer. 2021 May 2. doi: 10.1002/cncr.33590.
    PubMed     Abstract available


  17. PRINTZ C
    First Person Profile: Cheryl Willman, MD: As director and CEO of the University of New Mexico Comprehensive Cancer Center, Dr. Willman has led major health equity initiatives while making pioneering discoveries in precision medicine.
    Cancer. 2021;127:1357-1358.
    PubMed    


    April 2021
  18. MONTALBAN-BRAVO G, Kanagal-Shamanna R, Sasaki K, Masarova L, et al
    Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia.
    Cancer. 2021 Apr 29. doi: 10.1002/cncr.33622.
    PubMed     Abstract available


  19. IIJIMA M, Liu W, Panetta JC, Hudson MM, et al
    Association between obesity and neurocognitive function in survivors of childhood acute lymphoblastic leukemia treated only with chemotherapy.
    Cancer. 2021 Apr 29. doi: 10.1002/cncr.33624.
    PubMed     Abstract available


  20. ALLEN OS, Kim N, Morillo J, Smith CB, et al
    Assessment of prognostic understanding, perceived goals of care, and quality of life in hospitalized patients with leukemia or multiple myeloma.
    Cancer. 2021 Apr 23. doi: 10.1002/cncr.33599.
    PubMed     Abstract available


  21. JAMY OH, Godby R, Dhir A, Costa LJ, et al
    Impact of insurance status on the survival of younger patients diagnosed with acute promyelocytic leukemia in the United States.
    Cancer. 2021 Apr 23. doi: 10.1002/cncr.33593.
    PubMed     Abstract available


  22. PEMMARAJU N
    A call to action for the treatment of acute promyelocytic leukemia in the modern era: It is no longer just about the ATRA and arsenic.
    Cancer. 2021 Apr 23. doi: 10.1002/cncr.33594.
    PubMed    


  23. MORITA K, Kantarjian HM, Sasaki K, Issa GC, et al
    Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinib.
    Cancer. 2021 Apr 6. doi: 10.1002/cncr.33539.
    PubMed     Abstract available


  24. CALDWELL KJ, Budhraja A, Opferman JT, Pui CH, et al
    Activity of venetoclax against relapsed acute undifferentiated leukemia.
    Cancer. 2021 Apr 6. doi: 10.1002/cncr.33531.
    PubMed    


  25. SASAKI K, Ravandi F, Kadia TM, DiNardo CD, et al
    De novo acute myeloid leukemia: A population- based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017.
    Cancer. 2021 Apr 5. doi: 10.1002/cncr.33458.
    PubMed     Abstract available


  26. RAUSCH CR, DiNardo CD, Maiti A, Jammal NJ, et al
    Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia.
    Cancer. 2021 Apr 1. doi: 10.1002/cncr.33508.
    PubMed     Abstract available


  27. SASAKI K, Kantarjian HM, Short NJ, Samra B, et al
    Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors.
    Cancer. 2021 Apr 1. doi: 10.1002/cncr.33529.
    PubMed     Abstract available


  28. BENCOMO-ALVAREZ AE, Gonzalez MA, Rubio AJ, Olivas IM, et al
    Ethnic and border differences on blood cancer presentation and outcomes: A Texas population-based study.
    Cancer. 2021;127:1068-1079.
    PubMed     Abstract available


    March 2021
  29. AMONOO HL, LeBlanc TW, Kavanaugh AR, Webb JA, et al
    Posttraumatic stress disorder (PTSD) symptoms in patients with acute myeloid leukemia (AML).
    Cancer. 2021 Mar 25. doi: 10.1002/cncr.33524.
    PubMed     Abstract available


  30. JABBOUR E, Sasaki K, Short NJ, Ravandi F, et al
    Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Cancer. 2021 Mar 19. doi: 10.1002/cncr.33469.
    PubMed     Abstract available


  31. NAGLER A, Labopin M, Koc Y, Angelucci E, et al
    Outcome of T-cell-replete haploidentical stem cell transplantation improves with time in adults with acute lymphoblastic leukemia: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Cancer. 2021 Mar 19. doi: 10.1002/cncr.33522.
    PubMed     Abstract available


  32. KANTARJIAN HM, Kadia TM, DiNardo CD, Welch MA, et al
    Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.
    Cancer. 2021 Mar 18. doi: 10.1002/cncr.33477.
    PubMed     Abstract available


    February 2021
  33. VIVES S, Martinez-Cuadron D, Bergua Burgues J, Algarra L, et al
    A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia.
    Cancer. 2021 Feb 24. doi: 10.1002/cncr.33403.
    PubMed     Abstract available


    January 2021
  34. ORAN B, Saliba RM, Mehta RS, Alousi AM, et al
    Fractionated busulfan myeloablative conditioning improves survival in older patients with acute myeloid leukemia and myelodysplastic syndrome.
    Cancer. 2021 Jan 20. doi: 10.1002/cncr.33383.
    PubMed     Abstract available


  35. WOLFSON JA, Bhatia S, Ginsberg J, Becker LK, et al
    Expenditures among young adults with acute lymphoblastic leukemia by site of care.
    Cancer. 2021 Jan 19. doi: 10.1002/cncr.33413.
    PubMed     Abstract available


  36. ABOU DALLE I, Kantarjian HM, Ravandi F, Daver N, et al
    Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission.
    Cancer. 2021 Jan 15. doi: 10.1002/cncr.33409.
    PubMed     Abstract available


    December 2020
  37. BORTHAKUR G, Ofran Y, Tallman MS, Foran J, et al
    BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a study.
    Cancer. 2020 Dec 3. doi: 10.1002/cncr.33338.
    PubMed     Abstract available


  38. BADAR T, Szabo A, Dinner S, Liedtke M, et al
    Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia.
    Cancer. 2020 Dec 1. doi: 10.1002/cncr.33340.
    PubMed     Abstract available


    November 2020
  39. STOCK W, Martinelli G, Stelljes M, DeAngelo DJ, et al
    Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia.
    Cancer. 2020 Nov 24. doi: 10.1002/cncr.33321.
    PubMed     Abstract available


  40. TOPP MS, Gokbuget N, Zugmaier G, Stein AS, et al
    Long-term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab.
    Cancer. 2020 Nov 3. doi: 10.1002/cncr.33298.
    PubMed     Abstract available


    October 2020
  41. SHOUKIER M, Kadia T, Konopleva M, Alotaibi AS, et al
    Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations.
    Cancer. 2020 Oct 29. doi: 10.1002/cncr.33293.
    PubMed     Abstract available


  42. SEYMOUR EK, Ruterbusch JJ, Winn AN, George JA, et al
    The costs of treating and not treating patients with chronic myeloid leukemia with tyrosine kinase inhibitors among Medicare patients in the United States.
    Cancer. 2020 Oct 29. doi: 10.1002/cncr.33267.
    PubMed     Abstract available


  43. BATTIPAGLIA G, Labopin M, Hamladji RM, Blaise D, et al
    Post-transplantation cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLA-identical sibling donors: A retrospective analysis from the Acute Leukemia Working Par
    Cancer. 2020 Oct 29. doi: 10.1002/cncr.33255.
    PubMed     Abstract available


  44. BORTHAKUR G, Martinelli G, Raffoux E, Chevallier P, et al
    Phase 1 study to evaluate Crenigacestat (LY3039478) in combination with dexamethasone in patients with T-cell acute lymphoblastic leukemia and lymphoma.
    Cancer. 2020 Oct 27. doi: 10.1002/cncr.33188.
    PubMed     Abstract available


  45. CAYSSIALS E, Torregrosa-Diaz J, Leleu X, Guilhot F, et al
    Reply to Comment on low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective study.
    Cancer. 2020 Oct 23. doi: 10.1002/cncr.33281.
    PubMed    


  46. CAMPIOTTI L, Suter MB, Dentali F
    Comment on low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective study.
    Cancer. 2020 Oct 23. doi: 10.1002/cncr.33282.
    PubMed    


  47. RICHARD MA, Brown AL, Belmont JW, Scheurer ME, et al
    Genetic variation in the body mass index of adult survivors of childhood acute lymphoblastic leukemia: A report from the Childhood Cancer Survivor Study and the St. Jude Lifetime Cohort.
    Cancer. 2020 Oct 13. doi: 10.1002/cncr.33258.
    PubMed     Abstract available


    September 2020
  48. ROTZ SJ, Wei W, Thomas SM, Hanna R, et al
    Distance to treatment center is associated with survival in children and young adults with acute lymphoblastic leukemia.
    Cancer. 2020 Sep 10. doi: 10.1002/cncr.33175.
    PubMed     Abstract available


    August 2020
  49. KAROL SE, Cooper TM, Mead PE, Crews KR, et al
    Safety, pharmacokinetics, and pharmacodynamics of panobinostat in children, adolescents, and young adults with relapsed acute myeloid leukemia.
    Cancer. 2020 Aug 18. doi: 10.1002/cncr.33156.
    PubMed     Abstract available


  50. BLUM WG, Mims AS
    Treating acute myeloid leukemia in the modern era: A primer.
    Cancer. 2020 Aug 7. doi: 10.1002/cncr.32904.
    PubMed     Abstract available


    July 2020
  51. SOLEM CT, Bell TJ, Kwon Y, Cappelleri JC, et al
    A quality-adjusted survival time without symptoms or toxicities analysis of glasdegib plus low-dose cytarabine versus low-dose cytarabine as initial therapy for acute myeloid leukemia in patients who are not considered candidates for intensive chemoth
    Cancer. 2020 Jul 22. doi: 10.1002/cncr.33072.
    PubMed     Abstract available


  52. KIM MS, Prasad V
    US Food and Drug Administration approvals for Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukemia: Potential inefficiencies in trial design and evidence generation.
    Cancer. 2020 Jul 9. doi: 10.1002/cncr.33058.
    PubMed     Abstract available


    May 2020
  53. PEIPERT JD, Yount SE, Efficace F, Loefgren C, et al
    Validation of the Functional Assessment of Cancer Therapy-Leukemia instrument in patients with acute myeloid leukemia who are not candidates for intensive therapy.
    Cancer. 2020 May 28. doi: 10.1002/cncr.32977.
    PubMed     Abstract available


  54. CAYSSIALS E, Torregrosa-Diaz J, Gallego-Hernanz P, Tartarin F, et al
    Low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective study.
    Cancer. 2020 May 27. doi: 10.1002/cncr.32940.
    PubMed     Abstract available


  55. ORAN B, Garcia-Manero G, Saliba RM, Alfayez M, et al
    Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors.
    Cancer. 2020;126:2193-2205.
    PubMed     Abstract available


  56. GILL HS, Yim R, Kumana CR, Tse E, et al
    Oral arsenic trioxide, all-trans retinoic acid, and ascorbic acid maintenance after first complete remission in acute promyelocytic leukemia: Long-term results and unique prognostic indicators.
    Cancer. 2020 May 4. doi: 10.1002/cncr.32937.
    PubMed     Abstract available


    April 2020
  57. PRINTZ C
    Radiation from computed tomography scans is associated with increased risk for thyroid cancer and leukemia.
    Cancer. 2020;126:1601.
    PubMed    


  58. PRINTZ C
    Chemotherapy can induce relapse in some patients with leukemia.
    Cancer. 2020;126:1601.
    PubMed    


  59. RASHIDI A, Kaiser T, Graiziger C, Holtan SG, et al
    Gut dysbiosis during antileukemia chemotherapy versus allogeneic hematopoietic cell transplantation.
    Cancer. 2020;126:1434-1447.
    PubMed     Abstract available


    March 2020
  60. GARRETT-MAYER E
    Geographically distributed data should be analyzed with spatial epidemiologic methods.
    Cancer. 2020;126:1161-1162.
    PubMed    


  61. PALANDRI F, Breccia M, Bonifacio M, Polverelli N, et al
    Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis.
    Cancer. 2020;126:1243-1252.
    PubMed     Abstract available


  62. RAUSCH CR, Jabbour EJ, Kantarjian HM, Kadia TM, et al
    Optimizing the use of the hyperCVAD regimen: Clinical vignettes and practical management.
    Cancer. 2020;126:1152-1160.
    PubMed    


    January 2020
  63. PRINTZ C
    First person profile: Ching-Hon Pui, MD: An internationally renowned pediatric oncologist, Dr. Pui helped to push the cure rate for pediatric acute lymphoblastic leukemia to more than 90.
    Cancer. 2020;127:9-10.
    PubMed    


    June 2019
  64. PRINTZ C
    States that expanded medicaid coverage note increased patient use of hormonal therapies.
    Cancer. 2019;125:1767.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: